The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Use of the Inactivated Intranasal Influenza Vaccine and the Risk of Bell's Palsy in Switzerland
Open accessAbstract
BACKGROUND: After the introduction of an inactivated intranasal influenza vaccine that was used only in Switzerland, 46 cases of Bell's palsy were reported. METHODS: We conducted a matched case-control study and a case-series analysis. All primary care physicians, ear, nose, and throat specialists, and neurologists in German-speaking regions of Switzerland were requested to identify cases of Bell's palsy diagnosed in adults between October 1, 2000, and April 30, 2001. Each physician was invited to select three control patients for each patient with Bell's palsy, with matching according to age, date of the clinic visit, and physician. Vaccination information was provided by the physicians. RESULTS: A total of 773 patients with Bell's palsy were identified. Of the 412 (53.3 percent) who could be evaluated, 250 (60.7 percent) were enrolled and matched with 722 control patients; the other 162 patients had no controls. In the case-control study, we found that 68 patients with Bell's palsy (27.2 percent) and 8 controls (1.1 percent) had received the intranasal vaccine (P<0.001). In contrast to parenteral vaccines, the intranasal vaccine significantly increased the risk of Bell's palsy (adjusted odds ratio, 84.0; 95 percent confidence interval, 20.1 to 351.9). Even according to conservative assumptions, the relative risk of Bell's palsy was estimated to be 19 times the risk in the controls, corresponding to 13 excess cases per 10,000 vaccinees within 1 to 91 days after vaccination. In the case-series analysis, the period of highest risk was 31 to 60 days after vaccination. CONCLUSIONS: This study suggests a strong association between the inactivated intranasal influenza vaccine used in Switzerland and Bell's palsy. This vaccine is no longer in clinical use.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Belshe, R. B., Mendelman, P. M., Treanor, J., King, J., Gruber, W. C., Piedra, P., Bernstein, D. I., Hayden, F. G., Kotloff, K., Zangwill, K., et al. (1998) · New England Journal of Medicine · doi:10.1056/nejm199805143382002 · Cited by 916
Bell Palsy and Herpes Simplex Virus: Identification of Viral DNA in Endoneurial Fluid and Muscle
Murakami, S., Mizobuchi, M., Nakashiro, Y., Doi, T., Hato, N., & Yanagihara, N. (1996) · Annals of Internal Medicine · doi:10.7326/0003-4819-124-1_part_1-199601010-00005 · Cited by 743
Relative Incidence Estimation from Case Series for Vaccine Safety Evaluation
Farrington, C. P. (1995) · Biometrics · doi:10.2307/2533328 · Cited by 367
Incidence, clinical features, and prognosis in Bell's palsy, Rochester, Minnesota, 1968–1982
Katusic, S. K., Beard, C. M., Wiederholt, W. C., Bergstralh, E. J., & Kurland, L. T. (1986) · Annals of Neurology · doi:10.1002/ana.410200511 · Cited by 356
Adour, K. K., Ruboyianes, J. M., Trent, C. S., Doersten, P. G. V., Quesenberry, C. P., Byl, F. M., & Hitchcock, T. (1996) · Annals of Otology Rhinology & Laryngology · doi:10.1177/000348949610500508 · Cited by 296
Deaths: leading causes for 2000.
Anderson, R. N. (2002) · PubMed · Cited by 283
The epidemiology and treatment of Bell’s palsy in the UK
Rowlands, S., Hooper, R., Hughes, R., & Burney, P. (2002) · European Journal of Neurology · doi:10.1046/j.1468-1331.2002.00343.x · Cited by 237
Case Series Analysis of Adverse Reactions to Vaccines: A Comparative Evaluation
Farrington, C. P., Nash, J., & Miller, E. (1996) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a008695 · Cited by 235
A dilemma for mucosal vaccination: efficacy versus toxicity using enterotoxin-based adjuvants
Fujihashi, K., Koga, T., van Ginkel, F. W., Hagiwara, Y., & McGhee, J. R. (2002) · Vaccine · doi:10.1016/s0264-410x(02)00155-x · Cited by 175
Manipulating the immune system: humoral versus cell-mediated immunity
McNeela, E. A., & Mills, K. H. G. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(01)00169-7 · Cited by 106
Cited by
Mucosal vaccines: the promise and the challenge
Neutra, M. R., & Kozlowski, P. A. (2006) · Nature Reviews Immunology · doi:10.1038/nri1777 · Cited by 1,223
Nanotechnology: Intelligent Design to Treat Complex Disease
Couvreur, P., & Vauthier, C. (2006) · Pharmaceutical Research · doi:10.1007/s11095-006-0284-8 · Cited by 948
Vaccines for preventing influenza in healthy adults
Jefferson, T., Di Pietrantonj, C., Rivetti, A., Bawazeer, G. A., Al-Ansary, L. A., & Ferroni, E. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001269.pub4 · Cited by 896
Recent progress in mucosal vaccine development: potential and limitations
Lycke, N. (2012) · Nature Reviews Immunology · doi:10.1038/nri3251 · Cited by 807
Early Treatment with Prednisolone or Acyclovir in Bell's Palsy
Sullivan, F. M., Swan, I. R. C., Donnan, P. T., Morrison, J. M., Smith, B. H., McKinstry, B., Davenport, R. J., Vale, L. D., Clarkson, J. E., Hammersley, V., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa072006 · Cited by 771
Mucosal vaccines — fortifying the frontiers
Lavelle, E. C., & Ward, R. W. (2022) · Nature Reviews Immunology · doi:10.1038/s41577-021-00583-2 · Cited by 752
NALT- versus PEYER'S-patch-mediated mucosal immunity
Kiyono, H., & Fukuyama, S. (2004) · Nature Reviews Immunology · doi:10.1038/nri1439 · Cited by 745
Tutorial in biostatistics: the self‐controlled case series method
Whitaker, H. J., Paddy Farrington, C., Spiessens, B., & Musonda, P. (2006) · Statistics in Medicine · doi:10.1002/sim.2302 · Cited by 719
mRNA vaccine delivery using lipid nanoparticles
Reichmuth, A. M., Oberli, M. A., Jaklenec, A., Langer, R., & Blankschtein, D. (2016) · Therapeutic Delivery · doi:10.4155/tde-2016-0006 · Cited by 624
Nasal drug delivery devices: characteristics and performance in a clinical perspective—a review
Djupesland, P. G. (2013) · Drug Delivery and Translational Research · doi:10.1007/s13346-012-0108-9 · Cited by 563
GIUDICE, E., & CAMPBELL, J. (2006) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2005.12.003 · Cited by 496
Induction of secretory immunity and memory at mucosal surfaces
Brandtzaeg, P. (2007) · Vaccine · doi:10.1016/j.vaccine.2006.12.001 · Cited by 472
Nanogel antigenic protein-delivery system for adjuvant-free intranasal vaccines
Nochi, T., Yuki, Y., Takahashi, H., Sawada, S.-I., Mejima, M., Kohda, T., Harada, N., Kong, I. G., Sato, A., Kataoka, N., et al. (2010) · Nature Materials · doi:10.1038/nmat2784 · Cited by 468
Modern Subunit Vaccines: Development, Components, and Research Opportunities
Moyle, P. M., & Toth, I. (2013) · ChemMedChem · doi:10.1002/cmdc.201200487 · Cited by 464
Mitragotri, S. (2005) · Nature Reviews Immunology · doi:10.1038/nri1728 · Cited by 395
Vaccine adjuvant systems: Enhancing the efficacy of sub-unit protein antigens
Perrie, Y., Mohammed, A. R., Kirby, D. J., McNeil, S. E., & Bramwell, V. W. (2008) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2008.04.036 · Cited by 333
Unadjuvanted intranasal spike vaccine elicits protective mucosal immunity against sarbecoviruses
Mao, T., Israelow, B., Peña-Hernández, M. A., Suberi, A., Zhou, L., Luyten, S., Reschke, M., Dong, H., Homer, R. J., Saltzman, W. M., et al. (2022) · Science · doi:10.1126/science.abo2523 · Cited by 331
The COVID-19 Vaccine Race: Challenges and Opportunities in Vaccine Formulation
Wang, J., Peng, Y., Xu, H., Cui, Z., & Williams, R. O. (2020) · AAPS PharmSciTech · doi:10.1208/s12249-020-01744-7 · Cited by 327
Lewis, D. J. M., Huo, Z., Barnett, S., Kromann, I., Giemza, R., Galiza, E., Woodrow, M., Thierry-Carstensen, B., Andersen, P., Novicki, D., et al. (2009) · PLoS ONE · doi:10.1371/journal.pone.0006999 · Cited by 305
Intradermal vaccine delivery: Will new delivery systems transform vaccine administration?
Lambert, P. H., & Laurent, P. E. (2008) · Vaccine · doi:10.1016/j.vaccine.2008.03.095 · Cited by 302
Honko, A. N., Sriranganathan, N., Lees, C. J., & Mizel, S. B. (2006) · Infection and Immunity · doi:10.1128/iai.74.2.1113-1120.2006 · Cited by 278
Defense Mechanisms against Influenza Virus Infection in the Respiratory Tract Mucosa
Tamura, S.-I., & Kurata, T. (2004) · Japanese Journal of Infectious Diseases · doi:10.7883/yoken.jjid.2004.236 · Cited by 276
Oral intake of Lactobacillus fermentum CECT5716 enhances the effects of influenza vaccination
Olivares, M., Díaz-Ropero, M. P., Sierra, S., Lara-Villoslada, F., Fonollá, J., Navas, M., Rodríguez, J. M., & Xaus, J. (2007) · Nutrition · doi:10.1016/j.nut.2007.01.004 · Cited by 264
Tregoning, J. S., Russell, R. F., & Kinnear, E. (2018) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2017.1415684 · Cited by 263
Schattner, A. (2005) · Vaccine · doi:10.1016/j.vaccine.2005.03.005 · Cited by 257
Norton, E. B., Lawson, L. B., Freytag, L. C., & Clements, J. D. (2011) · Clinical and Vaccine Immunology · doi:10.1128/cvi.00538-10 · Cited by 221
Enhancing Oral Vaccine Potency by Targeting Intestinal M Cells
Azizi, A., Kumar, A., Diaz-Mitoma, F., & Mestecky, J. (2010) · PLoS Pathogens · doi:10.1371/journal.ppat.1001147 · Cited by 180
The Mucosal Vaccine Adjuvant LT(R192G/L211A) or dmLT
Clements, J. D., & Norton, E. B. (2018) · mSphere · doi:10.1128/msphere.00215-18 · Cited by 177
Bell's palsy and SARS-CoV-2 vaccines
Ozonoff, A., Nanishi, E., & Levy, O. (2021) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(21)00076-1 · Cited by 158
Lei, W.-T., Shih, P.-C., Liu, S.-J., Lin, C.-Y., & Yeh, T.-L. (2017) · Nutrients · doi:10.3390/nu9111175 · Cited by 134
“However, there remain some safety concerns regarding this process [5].”
BackgroundRafati, A., Pasebani, Y., Jameie, M., Yang, Y., Jameie, M., Ilkhani, S., Amanollahi, M., Sakhaei, D., Rahimlou, M., & Kheradmand, A. (2023) · JAMA Otolaryngology–Head & Neck Surgery · doi:10.1001/jamaoto.2023.0160 · Cited by 45
General determination of causation between Covid-19 vaccines and possible adverse events
Hampton, L. M., Aggarwal, R., Evans, S. J. W., & Law, B. (2021) · Vaccine · doi:10.1016/j.vaccine.2021.01.057 · Cited by 21
Metadata
- Authors
- Mutsch, M., Zhou, W., Rhodes, P., Bopp, M., Chen, R. T., Linder, T., Spyr, C., & Steffen, R.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2004-02-26
- Volume
- 350
- Issue
- 9
- Pages
- 896-903
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2002392006
- Cited by
- 916
- References
- 14
- FWCI
- 26.37
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.